Skip to content

US · BME · ASSET MANAGEMENT

BlackRock Health Sciences Trust (BME) intrinsic value and stock valuation

$43.96as of 2026-11-21 · Mkt cap 561.55M

Data updated · price as of 2026-11-21

UndervaluedIC value is 20–50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

BlackRock Health Sciences Trust DCF and intrinsic value

InvestorsCraft values BME with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from BME’s statements →

BlackRock Health Sciences Trust Graham Number

Graham Number: $76.30d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Financial Services · Asset Management Wilmington, NY 10001 blackrock.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$36.2M-14.7% 5y CAGRd
20192025
Net income
$77M-0.7% 5y CAGRd
20192025
Free cash flow
-$-4.35M
20192025
Total equity
$568.3M+0.8% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$36.2M$24.1M$34.9M-$-25.97M$53.2M
Operating income$77M$23.5M$8.46M-$-26.46M$59.1M
Net income$77M$23.5M$20M-$-26.47M$59.1M
EPSd$5.92M$1.77M$1.44M-$-2.1M$523.7K
Operating cash flow-$-4.35M$65.5M$32M-$-870K-$-21.56M
Capital expenditure-$0.00$0.00-$0.00$0.00-$0.00
Free cash flow-$-4.35M$65.5M$32M-$-870K-$-21.56M
Total assets$570.1M$774.6M$596.1M$606.1M$648.8M
Total debt$890K$300K$60K$0.00$210K
Net debt$890K-$-70K-$0.00-$0.00-$0.00
Total equity$568.3M$768.6M$588.1M$600.2M$625.8M
Cash and short-term investments$4.92M$26.6M$0.00$0.00$0.00
Income statement
20252024202320222021
Revenue$36.2M$24.1M$34.9M-$-25.97M$53.2M
Cost of revenue$5.63M$0.00$6.02M$5.94M$6.11M
Gross profit$30.5M$24.1M$28.9M-$-25.97M$47.1M
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$440K$360K$300K$360K$6.35M
Other expenses-$-46.9M$260K$90K-$-26.33M-$-5.81M
Operating expenses-$-46.46M$620K$390K-$-25.97M$540K
Cost and expenses-$-40.84M$620K$14.9M-$-25.97M-$-5.95M
Interest income$7.72M$0.00$0.00$0.00$0.00
Interest expense$50K$0.00$0.00$0.00$0.00
Depreciation and amortization$0.00$0.00$0.00$230K$0.00
Ebitda$77M$23.5M$20M-$-26.23M$59.1M
Operating income$77M$23.5M$8.46M-$-26.46M$59.1M
Total other income/expenses, net-$-30K$0.00$11.6M-$-10K-$-10K
Income before tax$77M$23.5M$20M-$-26.47M$59.1M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income$77M$23.5M$20M-$-26.47M$59.1M
Weighted average shares outstanding$13M$13.3M$13.9M$12.6M$112.9M
Weighted average diluted shares outstanding$13M$13.3M$13.9M$12.6M$112.9M
Balance sheet
20252024202320222021
Cash and short-term investments$4.92M$26.6M$0.00$0.00$0.00
Net receivables$430K$1.2M$1.58M$2.37M$3.18M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$5.34M$26.6M-$-40K$0.00$0.00
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$564.8M$773.3M$594.4M$603.7M$645.5M
Total non-current assets$564.8M$550M$594.4M$606.1M$648.8M
Total assets$570.1M$774.6M$596.1M$606.1M$648.8M
Accounts payable$210K$490K$0.00$230K$12.5M
Short-term debt$0.00$20K$60K$0.00$210K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$0.00$0.00$0.00$0.00$12.5M
Long-term debt$890K$150K$60K$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.83M$3.75M$7.97M$5.7M$10.6M
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$1.83M$6.03M$7.97M$5.93M$23M
Common stock$357.6M$942.1M$417.6M$424.3M$390.5M
Retained earnings$210.7M-$-173.53M$170.5M$175.9M$235.3M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$568.3M$768.6M$588.1M$600.2M$625.8M
Total investments$569.7M$799.8M$594.4M$603.7M$645.5M
Total debt$890K$300K$60K$0.00$210K
Net debt$890K-$-70K-$0.00-$0.00-$0.00
Cash flow statement
20252024202320222021
Net income$77M$23.5M$20M-$-26.47M$59.1M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital$740K$510K-$-770K$330K$250K
Accounts receivable-$-30K$220K-$-20K-$-150K$10K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$90K-$-20K-$-20K-$0.00$0.00
Net cash provided by operating activities-$-4.35M$65.5M$32M-$-870K-$-21.56M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$37.3M$66.4M$34.8M-$-11.62M-$-40K
Common stock issued$0.00$0.00$3.02M$33.6M$50.3M
Common stock repurchased-$-13.98M-$-29.53M$0.00$0.00$0.00
Dividends paid-$-40.61M-$-35.92M-$-35.1M-$-32.73M-$-29M
Net cash used for financing activities-$-54.59M-$-65.52M-$-32.02M$880K$21.3M
Net change in cash-$-10K$10K-$0.00$0.00-$-210K
Cash at end of period$0.00$10K$0.00$0.00$0.00
Operating cash flow-$-4.35M$65.5M$32M-$-870K-$-21.56M
Capital expenditure-$0.00$0.00-$0.00$0.00-$0.00
Free cash flow-$-4.35M$65.5M$32M-$-870K-$-21.56M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About BlackRock Health Sciences Trust

        BlackRock Health Sciences Trust is a closed-ended equity mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC. It invests in the public equity markets of the United States. The fund seeks to invest in stocks of companies operating in the health sciences and related sectors, which include businesses involved in researching, developing, producing, distributing or delivering medical, dental, optical, pharmaceutical or biotechnology products, supplies, equipment, or services. It also invests through equity derivatives, with an emphasis on option writing. The fund benchmarks the performance of its portfolio against the Russell 3000 Healthcare Index. BlackRock Health Sciences Trust was formed on March 31, 2005 and is domiciled in the United States.

        CEO
        John Perlowski
        Employees
        0
        Beta
        0.58

        Explore

        Frequently asked questions

        What is the intrinsic value of BlackRock Health Sciences Trust (BME)?

        BlackRock Health Sciences Trust (BME) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is BME undervalued?

        BME trades at a price of $43.96 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.